- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
- Interventions
- indium In 111 pentetreotide
- Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2004
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
- Interventions
- Talimogene laherparepvec, Paclitaxel
- Biological · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Nab paclitaxel, Gemcitabine, Cisplatin, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 345
- States / cities
- Anchorage, Alaska • Goodyear, Arizona • Phoenix, Arizona + 253 more
- Conditions
- DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
- Interventions
- Delayed SLND, Late SLND
- Diagnostic Test
- Lead sponsor
- Uppsala University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Gallbladder Cancer AJCC V7, Stage III Hepatocellular Carcinoma AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Carcinoma
- Interventions
- Durvalumab, Guadecitabine
- Biological · Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Newport Beach, California • Baltimore, Maryland
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v6, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
- Interventions
- External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Whole Breast Irradiation
- Radiation · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2040
- U.S. locations
- 7
- States / cities
- Gilbert, Arizona • Orlando, Florida • Conroe, Texas + 3 more
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Breast Adenocarcinoma, Breast Ductal Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma, Progesterone Receptor-Positive Breast Carcinoma
- Interventions
- Biospecimen Collection, BRC-001, Placebo Administration, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Interventions
- Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more
- Conditions
- Breast Cancer
- Interventions
- fluvastatin sodium, Breast Cancer Surgery Only - Arm III
- Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 4
- States / cities
- San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 1 more
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular, Carcinoma, Renal Cell, Carcinoma, Renal, Carcinoma, Small Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Neuroendocrine, Carcinoma, Thymic, Carcinoma, Pancreatic, Carcinoma Breast, Carcinoma, Ovarian, Carcinoma Bladder, Carcinoma of Unknown Primary, Carcinoma of the Head and Neck, Carcinoma of the Oropharynx, Carcinoma of the Larynx, Carcinoma of the Bladder, Carcinoma of Esophagus, Carcinoma of the Nasopharynx, Carcinoma of the Penis, Carcinoma of the Cervix, Carcinoma of the Anus, Carcinoma of the Vulva, Carcinoma of the Appendix, Carcinoma of the Oral Cavity, Cholangiocarcinoma, Melanoma, Mesothelioma, Pancreatic Cancer
- Interventions
- Not listed
- Lead sponsor
- Travera Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Ductal Carcinoma in Situ, Breast Cancer
- Interventions
- Novel cavity marking technique
- Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
- Interventions
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 578
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor
- Interventions
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 142
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more
- Conditions
- Breast Carcinoma, Breast Ductal Carcinoma in Situ
- Interventions
- Patient Navigation, Questionnaire
- Behavioral · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Atypical Ductal Breast Hyperplasia, Breast Cancer, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
- Interventions
- atorvastatin calcium, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors
- Interventions
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more
- Conditions
- Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- PEN-866 Sodium, fluorouracil, Folinic acid, Niraparib
- Drug
- Lead sponsor
- Tarveda Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 16
- States / cities
- Springdale, Arkansas • Denver, Colorado • Fort Myers, Florida + 13 more
- Conditions
- Metastatic Pancreatic (Ductal) Adenocarcinoma, Epithelial Ovarian Cancer, Malignant Epithelial Pleural Mesothelioma
- Interventions
- CART-meso
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cardiovascular Disorder, Chronic Kidney Disease, Metastatic Renal Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
- Interventions
- Best Practice, Blood Pressure Measurement, Clinical Management, Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 25
- States / cities
- Creve Coeur, Missouri • St Louis, Missouri • The Bronx, New York + 18 more
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ, Obesity, Overweight, Premalignant Lesion
- Interventions
- Behavioral, Psychological or Informational Intervention, Questionnaire Administration
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 30 Years to 70 Years · Female only
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Head and Neck Cancer
- Interventions
- Patient-specific dosimetry
- Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
- Interventions
- Selpercatinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Aurora, Colorado • Orlando, Florida + 9 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
- Interventions
- VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine, Gemcitabine + Nab-paclitaxel
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 295 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- RO7496353, Atezolizumab, Capecitabine, S-1, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania